BYSI News and Press, BeyondSpring Inc. From 09/08/21

NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will present at and participate in the Morgan Stanl...

Recently announced Phase 3 lung cancer data is likely weaker than claimed given the lack of standard disclosure and a history of poor trial conduct. We identify inaccurate data reporting and contradictory management statements regarding critical trial issues. Both strongly suggest BYS...

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in  BeyondSpring  (NASDAQ: BYSI ) are certainly seeing a lot of green. Shares of BYSI stock are nearly 15% higher at the time of writing. This move comes on an otherwise flat day for the marke...

The healthcare industry is expected to witness increasing demand amid an aging population. As such, Wall Street analysts expect small-cap healthcare stocks BeyondSpring (BYSI) and SCYNEXIS (SCYX) to gain significantly in the coming months. So, it could be wise to add these two stocks to one&#...

Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and incidence of Grade 4 neutropenia. NEW YORK, Aug. 31, 2021 (GLOBE NEWSWIRE) -- ...

Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine. The company has completed a Phase II trial of the vaccine but hasn't released any data from the trial. BeyondSpring, a New York City-China ...

Shares of BeyondSpring (NASDAQ: BYSI) , a clinical-stage biotech company, have been surging this week in response to a lucrative new partnership with Jiangsu Hengrui Pharmaceuticals in China. Investors are justifiably excited about the partners' new agreement to commercialize and co...

Gainers: Ascendis Pharma (NASDAQ:ASND) +25%, Zomedica (NYSE:ZOM) +15%, ABVC BioPharma (OTCQB:ABVC) +15%, BeyondSpring (NASDAQ:BYSI) +13%, Cortexyme (NASDAQ:CRTX) +12%. Losers: Aditxt (NASDAQ:ADTX) -29%, Quanterix (NASDAQ:QTRX) -12%, Doxim...

Wanchunbulin, BeyondSpring’s 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and co-development rights for plinabulin in Greater China markets (“the Territory”...